Reuters logo
TEXT-S&P rates AmSurg Corp 'BB-'
November 7, 2012 / 8:15 PM / 5 years ago

TEXT-S&P rates AmSurg Corp 'BB-'

     -- U.S. ambulatory surgery center operator AmSurg Corp. plans to issue 
$250 million senior unsecured notes to repay borrowings from its revolving 
credit facility.
     -- We are assigning the company our 'BB-' corporate credit rating. We are 
also assigning the proposed notes our 'B' issue-level rating with a recovery 
rating of '6'. 
     -- Our stable rating outlook reflects our expectation that AmSurg will 
remain acquisitive and that same-center revenue will continue to grow at a 
moderate pace.

Rating Action
On Nov. 7, 2012, Standard & Poor's Ratings Services assigned Nashville, 
Tenn.-based surgery center operator AmSurg Corp. its 'BB-' corporate credit 
rating. The outlook is stable.

At the same time, we assigned the proposed $250 million senior unsecured notes 
our 'B' issue-level rating with a recovery rating of '6', indicating our 
expectation for negligible (0% to 10%) recovery for lenders in the event of a 
payment default. We expect the maturity to be eight to 10 years. 

The company also has an unrated $475 million revolving credit facility, of 
which $296 million is borrowed, and unrated $75 million senior secured notes. 

The ratings on AmSurg reflect what we consider to be the company's 
"significant" financial risk profile and "weak" business risk profile (as our 
criteria define the terms). At the time of the transaction, we expect 
lease-adjusted debt leverage to be about 3.3x, after repayment of the 
revolving credit facility. However, our base case assumes that the company 
will borrow from its revolver again to fund the acquisitions of 15 separate 
centers currently under letters of intent. In this case, debt leverage will 
temporarily increase to about 4.5x (not including acquired EBITDA), but we 
expect it to decline to 3.8x by the end of 2013; liquidity is adequate. Our 
base case also assumes low single-digit same-center growth based on slightly 
positive increases in revenue per case and some growth in surgical volumes 
following employment trends. While we expect the reimbursement environment to 
remain slightly positive and EBITDA margins of around 17.5% to remain stable, 
third-party reimbursement risks (as owner and operator of surgical facilities) 
dominate the weak business risk profile. We also assume $250 million of 
acquisitions in 2012 and $100 million in 2013 at a purchase multiple of 7x 
EBITDA. In 2011 and 2010, the company used $239 million and $54 million on 
acquisitions, respectively. We expect debt leverage to be 3.8x and funds from 
operations to debt to be about 20% at the end of 2013. AmSurg owns and 
operates 229 ambulatory surgery centers in 35 states with some geographic 
concentration in California, Arizona, Maryland, Florida, and Texas.

AmSurg's weak business risk profile reflects the vulnerability of the 
company's portfolio of surgery centers to significant reimbursement or 
regulatory changes related to outpatient surgery. A typical AmSurg surgery 
center is 51% owned by the company and 49% owned by the physician. This is in 
contrast to two of its largest competitors, United Surgical and Surgical Care 
Affiliates, who have pursed a joint venture model that includes a hospital, 
with good results. Still, AmSurg has been successful in growing its business 
with 3% same-center growth and overall revenue growth of 16% year to date. 
Because the facilities in this highly fragmented industry are organized as 
partnerships with physicians and hospitals (in some cases), AmSurg is subject 
to competition to both attract and retain physicians. In addition, it could 
face difficulties creating and retaining strong physician relationships at its 
acquired assets.

Reimbursement is a key credit risk. Currently, standalone patient surgery 
centers are reimbursed at around 56% of hospital-based surgery centers. This 
differential provides some downside protection because hospital-based centers 
get paid significantly more for the same procedure. Generally more restrictive 
government payors account for about 28% of the company's revenue. This is 
similar to its peers, with the exception of United Surgical Partners (where 
the contribution is less, at 18% of U.S. revenue). In the near term, we expect 
government reimbursement and commercial reimbursement to be modestly positive 
for ambulatory surgery center operators. Medicare reimbursement increased 1.6% 
payment for outpatient ambulatory surgery centers this year. The increase for 
Medicare rates is set at 0.6% for 2013. Sequestration could potentially have a 
2% negative impact on Medicare reimbursement rates next year, although the cut 
is not in our base case.

Moreover, AmSurg is highly concentrated in the area of gastroenterology, 
exposing it to reimbursement risk for certain procedures. Currently, the 
company derives about 55% of revenue from its gastroenterology surgery 
centers, which mostly perform colonoscopies. This could also be a source of 
growth as the aging population and market penetration are expected to be 
drivers of growth for this procedure. Still, AmSurg is vulnerable to 
reimbursement risk in this area. The remaining revenue is from multispecialty 
centers (32%) and ophthalmology (13%). Over the longer term, we expect AmSurg 
to further diversify as it acquires more multispecialty surgery centers. Its 
peers, United Surgical Partners, Surgical Care Affiliates, and Symbion are 
more diversified in areas of treatment specialty. Still, given the key 
reimbursement risks that these companies face, we consider them to also have 
weak business risk profiles.

The significant financial risk profile reflects pro forma debt leverage of 
3.3x at the time of the transaction and expected leverage at 3.8x at the end 
of 2013, assuming debt-financed acquisitions. For purposes of calculating 
leverage, we consider EBITDA after distributions to minority interests. To 
adjust for leases, we are capturing 51% of the reported lease obligation, 
given that AmSurg generally does not guarantee the minority owner (physicians) 
portion of the operating lease.
AmSurg's liquidity is adequate. Cash sources include a cash balance of $36 
million as of Sept. 30, 2012, and expected revolver availability of $422 
million before accounting for the expected acquisitions. We also expect 
operating cash flow after distributions to minority interests and minimal 
working capital investment to be about $115 million annually. Maintenance 
capital expenditures are expected to be about $25 million a year. Our 
assessment of AmSurg's liquidity profile incorporates the following 
expectations and assumptions:
     -- We expect coverage of uses to be about 1.4 this year, considering 
pending acquisitions.
     -- We expect AmSurg to have adequate covenant cushion under its senior 
credit facility.
     -- We expect net sources to be positive even if EBITDA declines 30%.
     -- An unlikely ability to absorb low-probability shocks, without the need 
for refinancing based on its current cash balance and expected cash flow.
     -- A generally satisfactory standing in credit markets. 

Recovery analysis
The complete recovery analysis will be published subsequently on RatingsDirect 
on the Global Credit Portal. 

Our stable rating outlook reflects our expectation that AmSurg's operating 
trends will materialize largely as we expect in our base case, supporting the 
company's acquisitive growth strategy while maintaining credit metrics 
consistent with a "significant" financial risk profile. We could lower the 
rating if the company pursues a more aggressive than expected debt-financed 
acquisition strategy or if reimbursement levels moderately decline and cause 
margins to decline by about 200 basis points, such that leverage was expected 
to remain significantly above 4x.

An upgrade is unlikely in the near term because we do not expect that the 
business risk profile would change and acquisitions financed with free cash 
flow and some debt will likely keep debt leverage above 3x.
Related Criteria And Research
     -- Business Risk/Financial Risk Matrix Expanded, Sept. 18, 2012
     -- Liquidity Descriptors For Global Corporate Issuers, Sept. 28, 2011
     -- Criteria Guidelines For Recovery Ratings, Aug. 10, 2009
     -- 2008 Corporate Criteria: Analytical Methodology, April 15, 2008

Ratings List
AmSurg Corp.
Corporate Credit Rating                BB-/Stable/--      

New Rating
Senior Unsecured
  US$250 mil nts due 2020              B                  
   Recovery Rating                     6                  

Complete ratings information is available to subscribers of RatingsDirect on 
the Global Credit Portal at All ratings affected 
by this rating action can be found on Standard & Poor's public Web site at Use the Ratings search box located in the left 

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below